[{"orgOrder":0,"company":"Made Scientific","sponsor":"Tevogen Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Partnership","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Made Scientific \/ Tevogen Bio","highestDevelopmentStatusID":"5","companyTruncated":"Made Scientific \/ Tevogen Bio"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Made Scientific \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Made Scientific \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Made Scientific","sponsor":"Sentinel BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"SENT-001","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Made Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Made Scientific \/ Sentinel BioTherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Made Scientific \/ Sentinel BioTherapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Made Scientific

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The partnership aims to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          September 08, 2025

                          Lead Product(s) : HG-CT-1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Hemogenyx Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Made Scientific is partnering with Sentinel BioTherapeutics to manufacture SENT-001, an allogeneic encapsulated cell therapy delivering IL-2 for solid tumor immunotherapy.

                          Product Name : SENT-001

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          July 15, 2025

                          Lead Product(s) : SENT-001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sentinel BioTherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Experts from both entities will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          March 15, 2021

                          Lead Product(s) : TVGN-489

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Tevogen Bio

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank